Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).
暂无分享，去创建一个
S. Robinson | R. V. van Montfort | M. Lamers | M. Walton | K. Boxall | G. Aherne | M. Garrett | M. Valenti | A. K. de Haven Brandon | Paul D. Eve | Alan T. Henley | F. Raynaud | S. Eccles | I. Collins | A. Hayes | G. Box | J. Reader | A. D. Brandon | Y. Jamin | Nathan Brown | M. Lainchbury | T. Matthews | I. Westwood | K. Cheung | James D. Osborne | T. McHardy | Thomas P Matthews | P. Leonard | Nicolas Proisy | R. V. Montfort